Currently available pharmacological OA treatments only improve pain or symptoms and are frequently associated with side effects. There are no approved disease-modifying osteoarthritic drugs (DMOADs) on the market yet. A DMOAD typically must show improvement in joint structure, and slow down the progression of cartilage, bone and synovium destruction, with or without an efficacy on joint pain. Therefore, molecular tools are crucial for diagnosing OA and monitoring intervention efficacy. I will talk about a new drug combination with disease-modifying properties and biomarkers for monitoring the destruction of the joint pre-and post-treatment.